--- title: "U.S. stock night trading opened with fluctuations: Celestica fell 7.03% in night trading; Cheetah Net Supply Chain fell 6.32% in night trading" type: "News" locale: "en" url: "https://longbridge.com/en/news/288643510.md" description: "Celestica fell 7.03% in the night session; Cheetah Net Supply Chain fell 6.32% in the night session; Tilly rose 15.99% in the night session; Verastem rose 7.73% in the night session; Jasper Therapeutics rose 5.43% in the night session" datetime: "2026-06-04T00:22:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288643510.md) - [en](https://longbridge.com/en/news/288643510.md) - [zh-HK](https://longbridge.com/zh-HK/news/288643510.md) --- # U.S. stock night trading opened with fluctuations: Celestica fell 7.03% in night trading; Cheetah Net Supply Chain fell 6.32% in night trading **U.S. Stock Night Market Opening Movements** Celestica fell 7.03% in the night market. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no\_news Cheetah Net Supply Chain fell 6.32% in the night market. Based on recent key news: 1. On June 1, the Securities and Exchange Commission announced that Cheetah Net Supply Chain has financial reporting issues, leading to a decline in investor confidence and a 6.32% drop in stock price. 2. The overall performance of the industry has been weak recently, with the logistics and supply chain sector affected by macroeconomic pressures, resulting in significant capital outflows that further exacerbated the stock price decline. 3. Analysts have generally lowered earnings forecasts, expecting a year-on-year decline in earnings per share for the second quarter. The market holds a pessimistic view on the company's future performance, putting pressure on the stock price. The logistics industry has shown weak performance recently, with significant macroeconomic pressures. **Top Gainers in the U.S. Stock Night Market** Tilly rose 15.99% in the night market. Based on recent key news: 1. On June 3, Tilly's announced its Q1 2026 financial report, with sales growth of 15.9% and a significant reduction in net losses. The company expects sales to continue to grow and achieve profitability in the second quarter, despite risks from inflation and consumer trends. This news boosted market confidence and drove the stock price up. 2. On June 3, Tilly's announced strong performance in its e-commerce and stores, expecting sales and profit margins to remain strong in the second quarter. This news further enhanced investor confidence in the company's future performance, leading to a rise in stock price. 3. On June 2, analysts projected Tilly's quarterly revenue to grow by 12.7%, reaching $121.3 million. Although analysts rated the company's stock as "hold," market expectations for the company's performance drove the stock price up. The retail industry has shown strong overall performance, with significant growth in e-commerce. Verastem rose 7.73% in the night market. Based on recent key news: 1. On June 3, Verastem announced that its KRAS G12D inhibitor VS-7375 received Fast Track designation from the U.S. FDA for the treatment of locally advanced or metastatic non-small cell lung cancer with KRAS G12D mutations. This news drove the stock price up. 2. On June 3, Verastem launched the Phase 2 TARGET-D 202 trial for advanced non-small cell lung cancer, further enhancing market confidence in its R&D capabilities. 3. On June 3, Verastem's KRAS G12D inhibitor showed good safety and regulatory progress in Phase II trials, and the company's cash reserves support operations until 2027, boosting investor confidence. The biopharmaceutical industry has shown strong performance recently, with regulatory progress driving stock price increases Jasper Therapeutics rose 5.43% in after-hours trading. Based on recent key news: 4. On June 1, Jasper Therapeutics announced that it is exploring strategic options, including a potential sale of the company, to maximize shareholder value. The company is developing the experimental drug briquilimab for the treatment of mast cell-driven diseases, such as chronic spontaneous and inducible urticaria and asthma. This news drove the stock price up by 5%. 5. On June 1, Jasper Therapeutics stated that its board will evaluate options including asset sales or licensing, partnerships, mergers, or a sale of the company, and may implement cost-cutting measures to maintain cash flow and regulatory compliance. This news further boosted market confidence. 6. On June 1, Jasper Therapeutics published a related announcement on the EDGAR system, detailing the background and plans for the company's strategic options. This announcement filled investors with expectations for the company's future development, driving the stock price up. The biotechnology industry has performed strongly recently, with significant capital inflows ### Related Stocks - [CLS.US](https://longbridge.com/en/quote/CLS.US.md) - [CTNT.US](https://longbridge.com/en/quote/CTNT.US.md) - [TLYS.US](https://longbridge.com/en/quote/TLYS.US.md) - [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md) - [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md) ## Related News & Research - [Prediction: This top artificial intelligence (AI) stock will double in 3 years](https://longbridge.com/en/news/294584242.md) - [Celestica CFO Mandeep Chawla disposes of common shares worth $292,888.31](https://longbridge.com/en/news/294743525.md) - [Cullinan Therapeutics (CGEM) Expected to Release Quarterly Earnings on Thursday](https://longbridge.com/en/news/294341758.md) - [Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial](https://longbridge.com/en/news/294751791.md) - [Verus Capital Partners LLC Grows Stock Holdings in Celestica, Inc. $CLS](https://longbridge.com/en/news/294580912.md)